Medical Devices - Dermatology & Radiation Oncology
Strategic Profile
The company recently received exclusive and dedicated CPT codes from CMS for SRT technology, ensuring clear reimbursement for non-melanoma skin cancer treatments. Sensus is positioned for high-margin revenue and market share gains in expanding oncology settings driven by rising skin cancer incidence.
Cyborg Score Rationale
New CPT codes provide reimbursement certainty and management expects this to drive system adoption, with profitability now targeted for 2026. However, the company faces revenue volatility and limited product diversification that constrains growth potential.
Top Insights
CMS published first-ever dedicated CPT codes for SRT in 2026 Physician Fee Schedule, removing long-standing reimbursement barriers.
Key risks include ongoing uncertainty with largest customer, unresolved regulatory issues with TDI product approval, and dependency on regulatory clearances for international expansion.
Company received MDSAP certification for SRT product portfolio and partnered with Radiology Oncology Systems for distribution.
Sensus Link, a cloud-based software and connectivity solution, expands advanced operating capabilities across SRT-100 system installed base.